Selected article for: "attenuated vaccine and immune response"

Author: Edison Ong; Mei U Wong; Anthony Huffman; Yongqun He
Title: COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning
  • Document date: 2020_3_21
  • ID: ld0vo1rl_9
    Snippet: The multiple sequence alignment and the resulting phylogeny of nsp3 protein showed that 174 this protein in SARS-CoV-2 was more closely related to the human coronaviruses SARS-CoV and 175 MERS-CoV, and bat coronaviruses BtCoV/HKU3, BtCoV/HKU4, and BtCoV/HKU9. We studied 176 the genetic conservation of nsp3 protein ( Figure 1A (Table S4 -5). In terms of linear B cell epitopes, there were 14 epitopes with BepiPred 195 scores over 0.55 and had at le.....
    Document: The multiple sequence alignment and the resulting phylogeny of nsp3 protein showed that 174 this protein in SARS-CoV-2 was more closely related to the human coronaviruses SARS-CoV and 175 MERS-CoV, and bat coronaviruses BtCoV/HKU3, BtCoV/HKU4, and BtCoV/HKU9. We studied 176 the genetic conservation of nsp3 protein ( Figure 1A (Table S4 -5). In terms of linear B cell epitopes, there were 14 epitopes with BepiPred 195 scores over 0.55 and had at least ten amino acids in length (Table S6) (Table 2 ). But the inactivated or attenuated whole virus vaccine might induce strong 218 adverse events. On the other hand, vaccines targeting the structural proteins induce a strong 219 immune response 23,32,33 . In some studies, these structural proteins, including the S and N proteins, 220 were reported to associate with the pathogenesis of coronavirus 24,34 and might raise safety 221 concern 11 . Our study applied state-of-the-art Vaxign reserve vaccinology (RV) and Vaxign-ML 222 only the S protein may induce high serum-neutralizing antibody titers but cannot induce complete 231 protection 10 . In addition, HCoV-NL63 also uses S protein and employs the angiotensin-converting 232 enzyme 2 (ACE2) for cellular entry, despite markedly weak pathogenicity 35 . This suggests that the 233 S protein is not the only factor determining the infection level of a human coronavirus. Thus, 234 alternative vaccine antigens may be considered as potential targets for COVID-19 vaccines. 235

    Search related documents:
    Co phrase search for related documents
    • adverse event and amino acid: 1
    • adverse event and antibody titer: 1, 2, 3
    • adverse event and art state: 1, 2
    • adverse event and human coronavirus: 1
    • adverse event and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • adverse event and potential target: 1
    • adverse event and SARS protein: 1, 2, 3, 4, 5, 6, 7, 8
    • adverse event and structural protein: 1
    • adverse event and virus vaccine: 1, 2, 3, 4
    • alternative vaccine and amino acid: 1
    • alternative vaccine and art state: 1
    • alternative vaccine and cell epitope: 1, 2
    • alternative vaccine and human coronavirus: 1, 2
    • alternative vaccine and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • alternative vaccine and infection level: 1
    • alternative vaccine and potential target: 1
    • alternative vaccine and SARS protein: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • alternative vaccine and structural protein: 1, 2
    • alternative vaccine and virus vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13